Peptalk← All compounds

Metabolic & Weight Management

Survodutide

Also known as BI 456906 · BI-456906

Emerging researchSubcutaneous injectionInvestigational; not approved by the FDA, EMA, or other major regulators for any indication as of mid-2026, with Phase 3 trials ongoing/reporting. Received US FDA Breakthrough Therapy designation (September 2024) for non-cirrhotic MASH with fibrosis, which expedites development but is not approval. As an unapproved investigational new drug it is not a legitimate compounding ingredient under 503A/503B; following the resolution of GLP-1 shortages, FDA enforcement discretion for compounded GLP-1 drugs ended in 2025, and compounded "research" versions are not FDA-evaluated. For athletes, GLP-1 receptor agonists are not on the WADA Prohibited List but appear on WADA's 2026 Monitoring Program.

Survodutide (BI 456906) is an investigational, oxyntomodulin-derived peptide developed by Boehringer Ingelheim in partnership with Zealand Pharma. It acts as a dual agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR); researchers describe GLP-1R activity as influencing appetite and energy intake while GCGR activity is associated with energy expenditure and hepatic metabolism. It has been evaluated in randomized, placebo-controlled human trials, including Phase 2 studies and the Phase 3 SYNCHRONIZE program for overweight/obesity and trials in metabolic dysfunction-associated steatohepatitis (MASH/NASH). As of mid-2026 it remains investigational and is not approved by the FDA or other major regulators, with key Phase 3 obesity readouts reported during 2026. The research base is built on human RCTs, but no regulatory body has cleared it for clinical use, and the evidence is still developing.

Studied / used for

  • Investigated for weight reduction in adults with overweight or obesity without type 2 diabetes
  • Studied for weight management in people with overweight or obesity and type 2 diabetes
  • Investigated for metabolic dysfunction-associated steatohepatitis (MASH/NASH) and associated liver fibrosis
  • Studied for cardiometabolic parameters associated with obesity

Commonly reported side effects

  • Nausea, commonly reported in trials, particularly during the dose-escalation phases of trials
  • Vomiting, commonly reported in trials
  • Diarrhea, commonly reported in trials
  • Constipation, commonly reported in trials
  • Decreased appetite and other gastrointestinal disturbances, commonly reported in trials
Emerging research. Active research; human evidence still developing. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds